Amgen
Amgen's AI position rests on proprietary data and in-house models, while revenue still comes entirely from drug sales. Q2 2026 (August 4) revenues were $10.1B (+10%), with volume-driven product sales up 9% — Repatha +37%, Evenity +38%, Tezspire +42%, Imdelltra +115% — and full-year guidance is $38.2-39.4B revenue and $22.30-23.50 non-GAAP EPS. AI moved into R&D leadership when James Bradner became EVP of R&D, AI and Data. deCODE genetics' population-scale dataset and the Freyja DGX SuperPOD remain the differentiated asset; the AMPLIFY protein language model is open-source. MariTide is in seven Phase 3 studies, with three type 2 diabetes trials starting in 2026.
Scenarios
deCODE genetics' population-scale genomic data, run on the Freyja DGX SuperPOD, is a target-identification asset no competitor can replicate, and AI now sits at R&D leadership level. Volume-driven growth (Repatha +37%, Tezspire +42% in Q2 2026) funds the programme without depending on it.
Generative biology is scientifically compelling but the clinical validation gap remains — no AI-originated Amgen asset has reached late-stage trials. AMPLIFY's weights are public, so the model itself is not a moat, and MariTide enters a GLP-1 market where Lilly and Novo are entrenched.
Key Factors to Watch
- ●AMPLIFY protein language model (open-source, with Mila) — capability signal rather than a proprietary moat
- ●deCODE genetics population-scale genomic data + Freyja DGX SuperPOD — the non-replicable data asset
- ●James Bradner named EVP R&D, AI and Data (2026) — AI elevated to R&D leadership level
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-09-26 | 7.2 | Positive | W39 rotation — HOLD 7.2. No AI disclosure after August 8; Bradner's EVP R&D, AI and Data role predates the stamp. Removed an unsourced '2x success rate, 2x timeline compression' AMPLIFY claim and reframed AMPLIFY as open-source, since only deCODE's data is proprietary. Summary moved to Q2 2026 (revenue $10.1B, +10%). |
| 2026-03-08 | 7.2 | Positive | Score 7.3→7.2 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 7.3 | Positive | Score 7.4->7.3 (are 8->7, aam 8->9). External research cross-ref: deCODE 200+ PB data moat and AMPLIFY model are leading but revenue is from drug sales (are=7). Freyja SuperPOD, dedicated CTO + SVP of AI justify aam=9 |
| 2026-03-08 | 7.4 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-09-26
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.